New drug HS-20136-2 enters first human safety trial

NCT ID NCT07483437

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug, HS-20136-2, in 38 healthy adults to see if it is safe and how the body handles it. Participants receive a single injection of either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. Since this is a Phase 1 trial, it focuses on safety and dosing, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HS-20136-2 injection

What could go wrong

This is a very early Phase 1 study in only 38 healthy people, so it cannot prove the drug works for any disease. The main goal is just safety, not treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CMAX Clinical Research Pty Ltd

    Adelaide, South Australia, 5000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••